YALE COMPREHENSIVE CANCER CENTER

我们请求继续支持耶鲁癌症中心和继续 被认定为NCI指定的综合性癌症中心。少校 该中心的重点是分子医学和分子医学的应用 新的生物学进入临床，带来预防方面的进展， 癌症的诊断和治疗。在此应用程序中，我们请求支持 14个研究项目，其中5个是新重组的项目 专注于连接实验室的特定疾病或科学推动力 和临床研究工作(癌症遗传学、基因治疗/医学 肿瘤学和血液学、干细胞生物学和移植、乳腺癌 研究淋巴瘤研究)和14个共享资源，其中6个是新的 自上次申请以来(生物统计学、医学信息学、快速病例 确定、基因治疗人类应用、遗传咨询和 基因打靶服务)。此外，一项关于前列腺癌的新研究计划 癌症已经由YCC成立并支持，前三个 研究项目和一项共享资源已被逐步淘汰。自.以来 上一份申请由于强有力的招聘努力，导致了新的人员配置 几个YCC计划，以及领导层和行政部门的变化 中心的结构。我们请求支持高级领导层， 计划总监的级别反映了他们在以下方面的实际时间承诺 该中心及其计划，并为足够的行政人员 确保青年文化中心继续顺利运作，并作为一个 综合性癌症中心。YCC拥有雄厚的研究基础，总共 5,400万美元的同行评议资金，其中1,390万美元 美元来自NCI的拨款，不包括CCSG。自上个月以来 提交的重大变化也导致了更实质性的临床 为数据管理和生物统计学提供强有力支持的试验计划 以及建立临床试验网络(耶鲁大学肿瘤学 网络或YON)，这将允许YCC成员灵活地测试 他们的研究成果对实际应用的影响 YCC集水区的癌症患者，包括不应得的人 在Yon机构的影响范围内的人口。

We request continued support for the Yale Cancer Center and the continued recognition as an NCI designated comprehensive cancer center. The major focus of the Center is in molecular medicine and the application of the new biology into the clinics to bring about progress in the prevention, diagnosis and treatment of cancer. In this application we request support for 14 research programs, five of which are new restructured programs focusing on specific diseases or scientific thrusts that bridge laboratory and clinical research efforts (Cancer Genetics, Genetic Therapy/Medical Oncology and Hematology, Stem Cell Biology and Transplant, Breast Cancer Research Lymphoma Research), and 14 shared resources, six of which are new since the last application (Biostatistics, Medical Informatics, Rapid Case Ascertainment, Genetic Therapy Human Applications, Genetic Counseling and Gene Targeting Service). In addition a new research program on prostate cancer has been established and supported by YCC, and three former research programs and one shared resource have been phases out. Since the last application a strong recruiting effort has led to restaffing of several YCC programs, and changes in leadership and administrative structure of the Center. We request support for the senior leadership, program directors at a level that reflects their actual time commitment to the center and its programs and for sufficient administrative staff to ensure the continued smooth functioning of the YCC and its evolution as a comprehensive cancer center. The YCC has a robust research base of a total of $54 million dollars in peer reviewed funding of which $13.9 million dollars comes from NCI grants exclusive of the CCSG. Since the last submission major changes have also resulted in a more substantial clinical trials program with strong support for data management and Biostatistics and the establishment of a clinical trials network (The Yale Oncology Network or YON), that will allow the YCC members the flexibility to test the impact of their research results on the practical applications for people with cancer in the YCC catchment area including the undeserved populations in the sphere of influence of YON institutions.